Hypopituitarism after Orthohantavirus Infection: What is Currently Known?


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
10 04 2019
Historique:
received: 19 03 2019
revised: 03 04 2019
accepted: 06 04 2019
entrez: 13 4 2019
pubmed: 13 4 2019
medline: 21 3 2020
Statut: epublish

Résumé

Several case reports have described hypopituitarism following orthohantavirus infection, mostly following Puumala virus. The pathogenesis of this seemingly rare complication of orthohantavirus infection remains unknown. This review explores the possible pathophysiological mechanisms of pituitary damage due to orthohantavirus infection. In only three out of the 28 reported cases, hypopituitarism was detected during active infection. In the remaining cases, detection of pituitary damage was delayed, varying from two months up to thirteen months post-infection. In these cases, hypopituitarism remained undetected during the acute phase of infection or only occurred weeks to months post infection. Both ischemic and hemorrhagic damage of the pituitary gland have been detected in radiographic imaging and post-mortem studies in the studied case reports series. Ischemic damage could be caused by hypotension and/or vasospasms during the acute phase of hemorrhagic fever with renal syndrome (HFRS) while hemorrhage could be caused by thrombocytopenia, thrombopathy, and other known causes of coagulation disorders during orthohantavirus infection. Also, hypophysitis due to the presence of auto-antibodies have been suggested in the literature. In conclusion, a significant number of case reports and series describe hypopituitarism after orthohantavirus infection. In most cases hypopituitarism was diagnosed with a delay and therefore could very well be underreported. Clinicians should be aware of this potential endocrine complication, with substantial morbidity, and if unrecognized, significant mortality.

Identifiants

pubmed: 30974852
pii: v11040340
doi: 10.3390/v11040340
pmc: PMC6521286
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Front Microbiol. 2016 Jul 19;7:1077
pubmed: 27486439
Infect Dis (Lond). 2016 Sep;48(9):682-7
pubmed: 27299174
Indian J Endocrinol Metab. 2013 Nov;17(6):996-1004
pubmed: 24381874
Endocrine. 2005 Mar;26(2):79-82
pubmed: 15888918
Viral Immunol. 2008 Jun;21(2):255-62
pubmed: 18419255
Front Immunol. 2014 Dec 18;5:649
pubmed: 25566260
Lancet. 2007 Apr 28;369(9571):1461-1470
pubmed: 17467517
Virology. 2010 Sep 15;405(1):70-80
pubmed: 20673746
Lancet. 2003 Feb 8;361(9356):520-2
pubmed: 12583962
Clin Infect Dis. 2002 Jul 1;35(1):96-101
pubmed: 12060884
J Intern Med. 1992 Jul;232(1):87-90
pubmed: 1353521
Ann Intern Med. 1953 Jan;38(1):77-101
pubmed: 13008317
Neth J Med. 2015 May;73(4):155-60
pubmed: 25968286
N Engl J Med. 1994 Jun 9;330(23):1651-62
pubmed: 8043090
Am J Pathol. 1955 Mar-Apr;31(2):201-21
pubmed: 14350062
Blood Coagul Fibrinolysis. 2011 Sep;22(6):468-72
pubmed: 21508829
Blood Coagul Fibrinolysis. 2000 Jul;11(5):461-83
pubmed: 10937808
Thromb Haemost. 2009 Dec;102(6):1030-41
pubmed: 19967132
Annu Rev Med. 1999;50:531-45
pubmed: 10073292
Scand J Infect Dis. 1995;27(5):515-7
pubmed: 8588146
Lancet Infect Dis. 2003 Oct;3(10):653-61
pubmed: 14522264
Front Microbiol. 2014 Dec 22;5:727
pubmed: 25566236
Indian J Endocrinol Metab. 2011 Jul;15(3):170-4
pubmed: 21897892
Medicine (Baltimore). 2016 Dec;95(52):e5689
pubmed: 28033261
Clin Microbiol Rev. 2010 Apr;23(2):412-41
pubmed: 20375360
Emerg Infect Dis. 2012 Jul;18(7):1180-3
pubmed: 22709722
Am J Trop Med Hyg. 2011 Feb;84(2):229-33
pubmed: 21292889
Am J Med. 1954 May;16(5):639-50
pubmed: 13148206
Pituitary. 2016 Dec;19(6):625-642
pubmed: 27503372
Microvasc Res. 2013 Sep;89:7-14
pubmed: 23651686
Endocrinol Diabetes Metab Case Rep. 2016;2016:
pubmed: 27857837
Endocr Rev. 2015 Dec;36(6):622-45
pubmed: 26414232
Front Microbiol. 2015 Mar 24;6:220
pubmed: 25852676
BMJ Case Rep. 2009;2009:
pubmed: 21691389
J Korean Med Sci. 2001 Jun;16(3):355-9
pubmed: 11410700
J Virol. 2010 May;84(9):4832-9
pubmed: 20181715
PLoS Negl Trop Dis. 2014 Jun 12;8(6):e2858
pubmed: 24921924
J Med Virol. 2012 Oct;84(10):1680-96
pubmed: 22930518
J Korean Med Sci. 2009 Feb;24(1):158-61
pubmed: 19270831
Clin Endocrinol (Oxf). 2016 Jan;84(1):85-91
pubmed: 26202013
J Clin Endocrinol Metab. 2008 Jul;93(7):2722-8
pubmed: 18430769
Nephron. 1992;61(2):234-5
pubmed: 1352859
Antiviral Res. 2013 Dec;100(3):589-604
pubmed: 24126075
AJNR Am J Neuroradiol. 1995 Jan;16(1):175-8; discussion 179-80
pubmed: 7900589
J Infect Dis. 2016 May 15;213(10):1632-41
pubmed: 26704613
Eur J Clin Microbiol Infect Dis. 2010 Jun;29(6):705-13
pubmed: 20397036
AJNR Am J Neuroradiol. 1986 Jul-Aug;7(4):633-7
pubmed: 2873738
J Korean Med Sci. 1987 Dec;2(4):201-11
pubmed: 3151765

Auteurs

Soerajja Bhoelan (S)

Department of Viroscience, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. b.s.Bhoelan@gmail.com.

Thomas Langerak (T)

Department of Viroscience, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. Thomas.langerak@erasmusmc.nl.

Danny Noack (D)

Department of Viroscience, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. d.noack@erasmusmc.nl.

Linda van Schinkel (L)

Department of Internal Medicine, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. l.gribling-vanschinkel@erasmusmc.nl.

Els van Nood (E)

Department of Internal Medicine, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. e.vannood@erasmusmc.nl.

Eric C M van Gorp (ECM)

Department of Viroscience, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. e.vangorp@erasmusmc.nl.

Barry Rockx (B)

Department of Viroscience, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. b.rockx@erasmusmc.nl.

Marco Goeijenbier (M)

Department of Viroscience, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. m.goeijenbier@erasmusmc.nl.
Department of Internal Medicine, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. m.goeijenbier@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH